TransBioLine

Predicting which potential medicines could be harmful to major organ systems is a major challenge during drug development. The TransBioLine project aims to develop biological markers (biomarkers) that will reliably indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system. The biomarkers, which the project hopes to get through regulatory qualification, include indicators of tissue damage, biomarkers to aid patient stratification, and standardised tests for the detection of the biomarkers. By the end of the project, the team will have set up an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, and it will be able to provide the scientific community, industry and patients with detailed data and information across a large spectrum of advanced safety biomarkers. Ultimately, the new markers will not only improve the safety of new drugs, but will contribute to the better diagnosis and management of diseases.